Vasoactive intestinal polypeptide tied to migrane attacks, Finds JAMA Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-08-11 04:45 GMT | Update On 2021-08-11 05:22 GMT

Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptides (PACAPs) are structurally and functionally related, yet different in their migraine-inducing properties.

However, it remains unclear whether the lack of migraine induction can be attributed to the only transient vasodilatory response after a 20-minute infusion of vasoactive intestinal polypeptide. A 2-hour infusion of vasoactive intestinal polypeptide caused migraine attacks, suggesting an important role of vasoactive intestinal polypeptide in migraine pathophysiology, reports a study.

The study is recently published in the JAMA Network.

Lanfranco Pellesi and colleagues from the Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark aimed to determine whether a 2-hour infusion of vasoactive intestinal polypeptide would provoke migraine attacks.

A randomized, double-blind, placebo-controlled, crossover study was conducted at the Danish Headache Center in Copenhagen, Denmark. Patients were eligible for inclusion if they were ages 18 to 40 years, weighed between 50 and 90 kg, had a diagnosis of migraine without aura as defined by the International Classification of Headache Disorders, and had a migraine frequency of 1 to 6 attacks per month.

Patients were randomly allocated to receive a 2-hour infusion of vasoactive intestinal polypeptide or placebo on 2 different days. The primary end point was the difference in incidence of experimentally induced migraine attacks during the observational period (0-12 hours) between vasoactive intestinal polypeptide and placebo.

The following findings were observed-

a.Twenty-one patients (17 [81%] women and 4 [19%] men; mean [range] age, 25.9 [19-40] years) were recruited in the study.

b.Fifteen patients (71%; 95% CI, 48%-89%) developed migraine attacks after vasoactive intestinal polypeptide compared with 1 patient (5%; 95% CI, 0%-24%) who developed a migraine attack after placebo (P < .001).
c.The VIP-induced migraine attacks mimicked patients' spontaneous attacks.
d.The area under the curve (AUC) of headache intensity scores (0-12 hours), as well as the AUC of the superficial temporal artery diameter (0-180 minute) were significantly greater after vasoactive intestinal polypeptide compared with placebo.

Therefore, it was concluded that a 2-hour infusion of vasoactive intestinal polypeptide caused migraine attacks, suggesting an important role of vasoactive intestinal polypeptide in migraine pathophysiology. Vasoactive intestinal polypeptide and its receptors could be potential targets for novel migraine drugs.

Pellesi L, Al-Karagholi MA, De Icco R, et al. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(8):e2118543. doi:10.1001/jamanetworkopen.2021.18543

Article Source : JAMA Network

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Vasoactive intestinal polypeptide tied to migrane attacks, Finds JAMA Study

Similar News

Behavioral Therapy Noninferior to Drug Treatment for Overactive Bladder in Parkinson’s Disease: JAMA

Study finds olfactory impairment to increase the risk of cognitive decline

Flu Vaccination May Cut Stroke Risk by Over 70 Percent in Elderly With Chronic Conditions: Study

Poststroke Depression Persists or Recurs in Majority of Affected Patients Over 5 Years: Study Finds

Vaginal Progesterone for Preterm Birth Prevention Not Tied to Neuropsychological Outcomes in Dichorionic Twins: Study

This Brain Hormone May Control Blood Sugar Without Insulin: Study Suggests

Surgical Serenity: How to Help Kids Cope with Anesthesia Anxiety?

Multiple Sclerosis May Begin 15 Years Earlier with Subtle Symptoms: Study Suggests